An Abbott Laboratories processing plant in Sturgis, Mich being investigated for cases of infant illness is being allowed to release some product that was processed before it was shut down.
Certain goods designed for infants and people with specific medical issues will be given out for free.
Abbott officials claimed they're doing it at the FDA's request to help with shortages of these specialty feeding items.
After a recall of Similac infant formula and other products in February, the Sturgis plant was forced to shut down. Cronobacter bacteria had infected many infants, one of whom died; cronobacter was identified in their systems and the formula they had drunk. Cronobacter bacteria were discovered in the factory during an inspection.
However, further examination revealed that the cronobacter strain that caused the infections was not the same as the one detected in the plant and that no food-contact surfaces had been contaminated.
On a case-by-case basis, Abbott is issuing cases of a nutrition supplement for people with uncommon metabolic diseases and others. The corporation stated that it is doing so at the FDA's request to assist reduce shortages.


World Bank Raises South Asia Growth Forecast to 6.9%
Dollar Retreats From 18-Month High as Euro Rebounds
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds
Japan Real Wages Rise 1.5%, Supporting BOJ Rate Hikes
Hengrui Shares Rise on $2.6 Billion Novo Nordisk Obesity Drug Deal
Robinhood Buys $25 Million in Bitcoin for Corporate Treasury
HSBC Plans Deep UK Wealth Job Cuts in AI Push
Trump Signs Order to Cut Routine Childhood Vaccines
Paramount Skydance Completes $110 Billion Warner Bros Discovery Deal
Gate Launches Gate Money as Crypto Super App Race Heats Up
3 clinical-grade skincare creams you really shouldn’t buy online
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise
Australia Consumer Confidence Plunges as RBA Rate Hike Hits Households
Constellation Brands Beats Q2 Estimates, Buys SpikedAde
HUTCHMED, AstraZeneca Seek FDA Approval for Lung Cancer Combo
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal 



